Literature DB >> 33484215

Catheter ablation of atrial fibrillation using ablation index-guided high-power technique: Frankfurt AI high-power 15-month follow-up.

Shaojie Chen1,2, Boris Schmidt1, Stefano Bordignon1, Shota Tohoku1, Verena C Urban1, Britta Schulte-Hahn1, K R Julian Chun1,3.   

Abstract

BACKGROUND: Radiofrequency (RF) high-power ablation appears to be a novel concept in treating atrial fibrillation (AF). The ablation-index (AI) has been linked with the durability of pulmonary vein isolation (PVI). To report the midterm clinical results of a new ablation strategy using AI-guided high-power (50 W) ablation (AI-HP). METHODS AND
RESULTS: Symptomatic AF patients were included and underwent wide-area circumferential PVI. Contact-force catheters were used, RF power was set to 50 W targeting AI values (550/400 for anterior/posterior) and interlesion distance 6 mm. Luminal esophageal temperature (LET) was monitored during the procedure; patients with LET ≥39°C underwent post-ablation esophageal-endoscopy. Seventy-two-hour-Holter ECGs were scheduled during follow-up. Procedural PVI was achieved in all (N = 122; mean age, 68.2 years; male, 71.3%) patients, rate of first-pass PVI was 96.7% per patient. Procedural mean RF time was 11.5 min, and mean RF time during posterior wall segment was 3.1 min. Per RF-lesion, the mean contact force, RF duration, AI, and impedance-drop at anterior/posterior wall were 26 ± 14 g/23 ± 12 g, 16.2 ± 7.5 s/8.8 ± 3.6 s, 552 ± 53/438 ± 47, and 13 ± 6 Ω/9 ± 5 Ω, respectively. Mean PVI procedural-time, 55.8 min; mean procedural fluoroscopic time, 5.6 min. Three (2.5%) patients had asymptomatic endoscopic small erosion/erythema esophageal lesions, no serious adverse events were observed. During a 15-month follow-up, overall single-procedure freedom from clinical recurrence of AF/atrial tachycardia (AT) off antiarrhythmic drug after blanking period was 85.2% (89.4% for paroxysmal AF, 80.4% for persistent AF).
CONCLUSION: The AI-HP (50 W) appears as an efficient ablation technique in treating AF and leads to a high single-procedure arrhythmia-free survival at 15 months.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  ablation; ablation index; atrial fibrillation; high power; pulmonary vein isolation

Year:  2021        PMID: 33484215     DOI: 10.1111/jce.14912

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  6 in total

1.  Optimal Lesion Size Index for Pulmonary Vein Isolation in High-Power Radiofrequency Catheter Ablation of Atrial Fibrillation.

Authors:  Chi Cai; Jing Wang; Hong-Xia Niu; Jian-Min Chu; Wei Hua; Shu Zhang; Yan Yao
Journal:  Front Cardiovasc Med       Date:  2022-04-07

2.  Effectiveness and Safety of High-Power Radiofrequency Ablation Guided by Ablation Index for the Treatment of Atrial Fibrillation.

Authors:  Xuefeng Zhu; Chunxiao Wang; Hongxia Chu; Wenjing Li; Huihui Zhou; Lin Zhong; Jianping Li
Journal:  Comput Math Methods Med       Date:  2022-08-12       Impact factor: 2.809

3.  Tailored Target Ablation Index Guided Pulmonary Vein Isolation in Treating Paroxysmal Atrial Fibrillation: A Single Center Randomized Study in Asian Population (AI-Asian-I).

Authors:  Qingsong Xiong; Jia Liao; Weijie Chen; Peilin Xiao; Huaan Du; Qushuai He; Yuehui Yin; Zhiyu Ling; Shaojie Chen
Journal:  Front Cardiovasc Med       Date:  2022-07-07

4.  Ablation index-guided ablation with milder targets for atrial fibrillation: Comparison between high power and low power ablation.

Authors:  Zheng Liu; Li-Feng Liu; Xiao-Qin Liu; Jiapeng Liu; Yu-Xin Wang; Ye Liu; Xing-Peng Liu; Xin-Chun Yang; Mu-Lei Chen
Journal:  Front Cardiovasc Med       Date:  2022-08-04

5.  Incremental predictive value of left atrial strain and left atrial appendage function in rhythm outcome of non-valvular atrial fibrillation patients after catheter ablation.

Authors:  Xin-Xin Ma; Aiqing Wang; Kaibin Lin
Journal:  Open Heart       Date:  2021-06

6.  Effects of Modified Simultaneous Unipolar Saline-Irrigated Radiofrequency Ablation in Patients with Atrial Fibrillation Combined with Mitral Valve Disease.

Authors:  Bo Jiang; Ji-Wei Gu; Yan-Yan Song; Lei Bai; Xu-Dong Liu; Yu-Jing Zhang; Ming-Liang Li; Jian Yang; Li Liu; Yun Wang
Journal:  Int J Gen Med       Date:  2021-05-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.